This video takes a look at what's next for Arena Pharmaceuticals and the rest of the obesity drug makers. With the first approved weight-loss drug in more than a decade, Arena is in the driver's seat, but success is not guaranteed.
Obesity drugs aren't the only huge story in health care right now. Even though the Supreme Court ruled the ACA is constitutional, that doesn't mean the health-reform fight is over. The 2012 elections loom large, but the Fool has you covered with our new special free report "These Stocks Could Skyrocket After the 2012 Presidential Election," where you'll get ideas for companies in health care and beyond that can benefit from each candidate's platform. Get your free copy.
David Williamson holds no position in any company mentioned. Check out his holdings and a short bio. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
A robust clinical-stage pipeline helped investors forget about Arena's ill-fated weight-loss drug.
The Single Event That Rocketed Arena Pharmaceuticals, Inc. Higher by 10% in October
You could say that Arena "posterized" Wall Street in October and was rewarded for it.
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Preclinical data strengthened the case for Arena's lead candidate.